Alkermes closes facility resulting in major job cuts
NEW YORK Alkermes has announced its decision to close its manufacturing facility in Chelsea, Mass., and cut 150 jobs as a result.
The company will be cutting 18 percent of its workers, effective this week, and will be offering severance pay, benefits and outplacement services to its workers, according to published reports. This will also result in a restructuring charge of about $5million to $10 million and a fourth-quarter impairment charge of about $15 million.
Eli Lilly’s decision to cancel the development of its AIR insulin program was the main factor in Alkermes closing of its facilities. Lilly and Alkermes were developing the diabetes drug jointly. Lilly’s explanation for its development cancellation was that the drug was not strong enough to compete with other products already on the market.
TMH gets FDA OK for AutoSafety Injector
SHEFFIELD, United Kingdom The Food and Drug Administration has granted 510(k) clearance to The Medical House for its Compact AutoSafety Injector.
This clearance allows for the device, which is used for assisting self–administered subcutaneous injections to enter the market.
According to Ian Townsend, chairman, The Medical House: “This a key milestone achievement for TMH as it is our first ASI device to receive FDA pre-market notification which allows us to market the CASI in the US. It is also a vital approval for the project involving our global pharmaceutical partner and its commercial strategy. We are all delighted with this news and we look forward to reporting more progress for our Drug Delivery Division in due course”.
HealthPort wins top honors at Texas EHR Summit
COLUMBIA, S.C. HealthPort was named one of the top two vendors at a recent event held by the Texas Association of Community Health Center entitled the TACHC EHR Summit last month. The company was one of eight national/international electronic health record companies selected to participate.
More than 15 EHR vendors were initially identified as having a community health center appropriate software solution, but the eight finalists were selected when they incorporated CHC-specific clinical and functional elements and then demonstrated how those elements were used in a CHC setting during a web based pre-screening event.
At the summit, a representative from each vendor captured clinical details in a 15-minute, timed-staged encounter. Immediately following each demonstration, audience participants used a keypad to vote on 6 criteria, providing the vendor and attendees immediate feedback on the look, feel, and functionality of the software.
“It was an honor and privilege to have been selected to attend the TACHC EHR Summit. The strength of our CHC product suite was acknowledged by attendees, illustrating why HealthPort has achieved significant CHC marketshare over the past 20 plus years,” says Kerry de Vallette, senior vice president of solution sales for HealthPort.